Cargando…
PRL3 as a therapeutic target for novel cancer immunotherapy in multiple cancer types
Phosphatase of Regenerating Liver-3 (PRL3) was discovered in 1998 and was subsequently found to be correlated with cancer progression and metastasis in 2001. Extensive research in the past two decades has produced significant findings on PRL3-mediated cancer signaling and functions, as well as its c...
Autores principales: | Chia, Pei Ling, Ang, Koon Hwee, Thura, Min, Zeng, Qi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091880/ https://www.ncbi.nlm.nih.gov/pubmed/37064866 http://dx.doi.org/10.7150/thno.79265 |
Ejemplares similares
-
PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse
por: Thura, Min, et al.
Publicado: (2021) -
Author Correction: PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse
por: Thura, Min, et al.
Publicado: (2021) -
Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody
por: Loh, Amos Hong Pheng, et al.
Publicado: (2023) -
PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
por: Thura, Min, et al.
Publicado: (2019) -
Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
por: Thura, Min, et al.
Publicado: (2021)